Document:

<PAGE>

                                                                    EXHIBIT 10.6

                      MARKETING AND DISTRIBUTION AGREEMENT

                                     between

   Diamed Medizintechnik GmbH, Stadtwaldgutel 77, 50935 Koln, Germany (DIAMED)

                                       and

   Occulogix, Inc., P.O. Box 2081, Palm Harbor, Florida 34682-2081 (Occulogix)

WHEREAS:

DIAMED has developed a device for the therapy of blood-and blood plasma for
various indications. The device is marketed under the trademarks Octo Nova and
Octo Therm which are registered in various countries. DIAMED owns all property
and marketing rights world wide for Octo Nova/Octo Therm and its future
developments. MESYS has engineered and produces Octo Nova/Octo Therm exclusively
on orders from DIAMED. For each Octo Nova/Octo Therm produced, DIAMED receives
compensation for amortization of development cost from MESYS. MESYS is the
manufacturer of Octo Nova/Octo Therm according to the European quality
standards, especially MDD and MPG. Agreements between DIAMED and MESYS provide
that only DIAMED is allowed to decide on production and marketing of the Octo
Nova/Octo Therm.

Occulogix desires to distribute Octo Nova/Octo Therm in its territory.

                         SECTION 1 PURPOSE OF AGREEMENT

The sole purpose of this agreement is to define the rights of Occulogix to
distribute Octo Nova/Octo Therm in its territory.

                                SECTION 2 PRODUCT

Product is the Octo Nov/Octo Term and its further developments during the life
of this agreement.

                               SECTION 3 TERRITORY

Territory is: USA, Canada, Mexico, Caribbean.

              SECTION 4 DISTRIBUTION RIGHTS, NON-COMPETITION CLAUSE

On the basis of this agreement, DIAMED permits Occulogix to enter into an
agreement with MESYS to purchase the product directly from MESYS and to market
and distribute it in the territory as an independent distributor.

This permission does not include any right for Occulogix to produce the product
or have produced the product by any third party.

<PAGE>

                                       -2-

Occulogix commits itself to purchase, market and distribute the product as it is
exclusively produced by MESYS.

With the exception of machine Model PP-04 (ATI) and Plasmatic (Kimal) Occulogix
commits itself to not market and distribute other devices, neither directly nor
indirectly in the territory which compete with the product or have a similar
application.

Occulogix shall enter into an agreement with MESYS for the production and
purchasing of products (hereafter "the Production Contract"). DIAMED is not
responsible whatsoever for the execution of obligations under such agreement,
namely and not limited to deliveries, warranties, product properties and product
liabilities.

       SECTION 5 EXCLUSIVITY, TRADEMARKS, PRODUCT CHANGES, OBLIGATIONS OF
                        DISTRIBUTION, MINIMUM QUANTITIES

1.    (a)   With this agreement, Occulogix acquires the exclusive rights to
            market and distribute the product in the territory. The marketing
            and distribution of the product, neither directly or indirectly
            outside of the territory is not permitted.

      (b)   Occulogix has the right and the obligation to distribute the product
            under the trademarks Octo Nova/Octo Therm. Any registration of
            trademarks in connection with the product in the territory must be
            approved by DIAMED in advance. Any cost involved is born by
            Occulogix. Upon termination of this marketing agreement, all rights
            associated with the product have to be transferred to DIAMED without
            compensation.

      (c)   Occulogix has the right to request product changes by MESYS at his
            expense. Any product change however, must be approved by DIAMED in
            writing and in advance.

      (d)   For the duration of this agreement, the rights on such product
            changes are passed over to the financing Occulogix with validity for
            its territory only. Upon termination of the agreement, all such
            rights are to be transferred to DIAMED without compensation. The
            rights for all other territories pass over to DIAMED immediately
            when developed and without compensation.

2.    Occulogix commits itself to undertake all possible and tolerable efforts
      to market and distribute the product optimally. Such obligations begin
      immediately with this contract coming into effect.

3.    Occulogix is obliged to promote the product in its territory with a
      reasonable and to the most effective extent by exhibitions,
      advertising-and sales activities or similar, appropriate action.

4.    In the case that Occulogix falls short of fulfilling the annual minimum
      quantities agreed upon in the production agreement with MESYS for two
      successive years, DIAMED is entitled to terminate this marketing agreement
      with 3 months notice or, upon the sole choice of DIAMED, to revise it to
      the effect that Occulogix shall not anymore be entitled

<PAGE>

                                       -3-

      to the exclusive marketing and distribution of the product in its
      territory. Any such termination or alteration has to be performed in
      writing by registered mail.

In the case that is agreement does not begin with a calendar year, twelve months
from the date of effectiveness shall be considered as one year.

                              SECTION 6 LICENSE FEE

Occulogix is obliged to pay to DIAMED an annual license fee for the use of the
exclusive rights in the amount of E3.000,-. It is payable within the first
month of each year in the sense of Section 5.4. In case that it is not paid in
due time and also is not paid within 60 days after receipt of a formal letter of
caution, Section 5.4 will become effective.

                    SECTION 7 TERM OF AGREEMENT, TERMINATION

1.    This agreement has a term of three (3) years from the date of
      effectiveness. It will become initially effective upon the effective date
      of the Production Contract between Occulogix and MESYS. The agreement
      terminates at that time without requiring specific termination. Any
      extension of this agreement must be agreed upon expressively in advance
      and in writing.

2.    This agreement can be terminated anytime by extraordinary termination due
      only to important reason. Important reasons are especially:

      (a)   Breach of essential regulations of this agreement by the other
            party, provided that it is not corrected within 60 days after
            receipt of a formal letter of caution.

      (b)   If the other party shall file a petition on bankruptcy, or shall be
            adjudicated a bankrupt, or shall become insolvent, or shall make an
            assignment for the benefit of creditors, or shall be voluntarily or
            involuntarily dissolved or shall have a receiver, trustee or other
            court officer appointed for its property.

      (c)   Termination of the production agreement between DIAMED and MESYS.

      (d)   Termination of the distribution agreement between MESYS and
            Occulogix.

3.    Termination of this agreement does not relieve either party from the
      execution of obligations entered into including any payment.

                             SECTION 8 REGISTRATION

1.    The Product has been registered and CE-marked within the EU-states for use
      according to the written documentation and instructions. The Product may
      only be operated in accordance to the instructions.

2.    The Product is not registered outside the EU-states. In case that such a
      registration or similar authorisation should be required, Occulogix
      commits itself to cooperate with MESYS in such a way that a registration
      or similar authorisation outside the EU-states

<PAGE>

                                       -4-

      will be accomplished. Also in this area, DIAMED has no responsibilities.
      Any cost occurring are to be born by Occulogix.

                               SECTION 9 LIABILITY

DIAMED is liable only for its intellectual property rights and its marketing
rights on the product. DIAMED will not be liable whatsoever, neither for the
execution of agreements between Occulogix and MESYS nor for the quality or other
properties of the product. In so far, all and any claims must be dealt with
directly between Occulogix and MESYS.

In particular, DIAMED is not liable that a Production Contract will be entered
into with MESYS. Such agreement shall be negotiated directly among Occulogix and
MESYS.

In the case that a damage to Occulogix should develop by action or omission on
the part of DIAMED and should this case be based on violation of contractual
obligations, DIAMED shall be liable only for actions of intent and gross
negligence. Any further liability is excluded.

       SECTION 10 PLACE OF EXECUTION, PLACE OF JURISDICTION, GOVERNING LAW

For any disputes from this agreement, the place of Execution and Place of
Jurisdiction shall be Cologne (Koln), Germany. German Law shall govern.

                            SECTION 11 MISCELLANEOUS

1.    The parties are in agreement that neither verbal nor written supplementary
      agreements besides this one have been made. Alterations and additions of
      this agreement are only valid if agreed in writing between the parties.
      Such requirement cannot be cancelled.

2.    In the case that certain regulations of this agreement should be void,
      this will not influence the effectiveness of the agreement in total. In
      such case, the parties commit themselves to replace the void regulation by
      an effective regulation which comes closest to the economic purpose of the
      void regulation.

3.    This marketing agreement has been drawn up in German and English language.
      However, in case of contradictions or differences among these two
      versions, only the German version is of binding nature.

Place/Date  _______________________

___________________________________        _____________________________________
DIAMED                                     Occulogix

<PAGE>

                                       -5-<PAGE>

                                                                    EXHIBIT 10.7

                         2002 OCCULOGIX/STOCK AGREEMENT

            THIS AGREEMENT, dated this      day of February, 2002, is entered
into by and between HANS K. STOCK, of Wullnerstrasse 145, 50935 Koln, Germany,
and OCCULOGIX CORPORATION, a Florida corporation with offices at 612 Florida
Avenue, Palm Harbor, Florida 34683 ("OCCULOGIX").

            NOW THEREFORE, for good and valuable consideration, the parties
hereto agree as follows:

1.    DEFINITIONS

      ASAHI/OCCULOGIX DISTRIBUTOR AGREEMENT. ("DISTRIBUTOR AGREEMENT") -- An
      exclusive sales, marketing and distributorship agreement (effective
      December 31, 2001) between OCCULOGIX and ASAHI for Asahi's Rheolfilter and
      Plasmaflo products to be used in the treatment of AMD and other ophthalmic
      diseases.

2.    RECITALS

      A.    The DISTRIBUTOR AGREEMENT between OCCULOGIX and ASAHI has been
            executed and is operative.

      B.    The DISTRIBUTOR AGREEMENT was procured with the assistance of STOCK.

3.    STOCK'S PROCUREMENT OF ADDITIONAL PRODUCTS FOR OCCULOGIX

      STOCK has heretofore assisted OCCULOGIX in procuring the DISTRIBUTOR
      AGREEMENT. The parties desire that STOCK further assist OCCULOGIX in
      procuring new product lines from ASAHI for marketing and distribution by
      OCCULOGIX. Accordingly, STOCK hereby agrees to assist OCCULOGIX, in the
      capacity of an independent contractor, to obtain new product lines from
      ASAHI which will be reduced to writing and upon terms which are fully and
      completely agreeable with OCCULOGIX. Such agreement shall provide, to the
      extent OCCULOGIX deems necessary, for unlimited access by OCCULOGIX to
      technical and clinical data and information relating to the product or
      products at issue. To the extent that STOCK is in possession of such
      technical and clinical data and information, he agrees to allow OCCULOGIX
      unlimited access thereto. To the extent that ASAHI or any other third
      party is in possession of such data and information, STOCK agrees to
      assist OCCULOGIX in the procurement thereof.

4.    ROYALTY OBLIGATIONS

      A.    OCCULOGIX remains obligated to pay royalties to STOCK for his
            assistance in procuring the DISTRIBUTOR AGREEMENT. OCCULOGIX shall
            henceforth

<PAGE>

                                       -2-

            pay to STOCK a 5% royalty on the purchase price from ASAHI for all
            products procured pursuant to the DISTRIBUTOR AGREEMENT. Such
            royalty payments shall be payable through the duration of the
            DISTRIBUTOR AGREEMENT but not thereafter except by written agreement
            of the parties.

      B.    All such royalty payments to STOCK shall be made in U.S. dollars
            within forty-five (45) days after the previous business quarter,
            accompanied by a full accounting of product purchases during such
            business quarter.

      C.    The right of STOCK to receive all such royalty payments shall
            survive the death of HANS K. STOCK and shall become a receivable of
            STOCK's estate until the termination of this Agreement.

      D.    If the DISTRIBUTOR AGREEMENT is extended or renegotiated at the end
            of their current term and OCCULOGIX requires STOCK's assistance in
            formulating that agreement, the royalty payments shall be negotiated
            with STOCK in a separate agreement at that time.

      E.    If the exclusivity of the DISTRIBUTOR AGREEMENT is terminated by
            ASAHI during the terms of said agreements, the obligation of
            OCCULOGIX to pay royalties to STOCK shall be terminated as well.
            OCCULOGIX shall be responsible for the payment of royalties to STOCK
            up to the day of the termination of exclusivity.

5.    DEFAULT AND REMEDIES

      A.    In the event that OCCULOGIX fails to perform its obligations under
            this Agreement, STOCK shall have as its exclusive remedy recovery of
            unpaid royalties provided that STOCK is entitled to recovery of same
            pursuant to the terms set forth above.

      B.    In the event that STOCK fails to comply with the terms of this
            Agreement, OCCULOGIX shall have as its exclusive remedy recovery of
            all ascertainable damages for interference with or impeding the
            DISTRIBUTOR AGREEMENT.

      C.    The parties hereto hereby stipulate and agree that this Agreement
            shall be governed and construed exclusively by the laws of the State
            of Florida and, in the event of suit, venue of such proceeding shall
            be in the Circuit Court for Pinellas County, Florida. The prevailing
            party in such suit shall have the right to recover attorney's fees
            through any appeal. This Agreement shall inure to the benefit of any
            successor in interest to OCCULOGIX whether by merger or otherwise;
            but the parties agree and stipulate that there are no other
            attendant or incidental beneficiaries to this Agreement.

6.    ENTIRE AGREEMENT

      This Agreement constitutes the entire understanding of the parties hereto
relating to the subject matter hereof and supersedes all prior agreements or
understandings with respect to the

<PAGE>

                                       -3-

subject matter hereof among the parties. This Agreement may be amended, and the
observance of any term of this Agreement may be waived, with the written consent
of each of the parties hereto. Any such waiver does not imply or express that
any other similar or dissimilar waiver shall be granted or agreed to by the
parties.

                                              OCCULOGIX
__________________________________________
          HANS K. STOCK

                                              By: ______________________________

                                              Its: _____________________________
                                                             [title]

Signed, sealed and delivered in the presence of:

As to STOCK:                                      As to OCCULOGIX:

Date: ____________________________________  Date: ______________________________

__________________________________________  ____________________________________
[signature, Witness]                        [signature, Witness]

             "Beatrice Birkhole"                    "John Cornish"
__________________________________________  ____________________________________
[typed/printed name]                        [typed/printed name]

Address: _________________________________  Address: ___________________________

__________________________________________  ____________________________________

__________________________________________  ____________________________________

__________________________________________  ____________________________________
[signature, Witness]                                 [signature, Witness]

             "Angelina KimKar"                     "Susan B. Howard"
__________________________________________  ____________________________________
[typed/printed name]                        [typed/printed name]

Address: _________________________________  Address: ___________________________

__________________________________________  ____________________________________

__________________________________________  ____________________________________

<PAGE>

                                       -4-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]